Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
- Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
- Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
- OTC news on brief
January 15, 2001
- Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
- Sankyo, Mochida Tie Up with Riken
January 15, 2001
- Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
- Asahi Chemical Invests US$9 Mil in Circe Biomedical
January 15, 2001
- Sumitomo Ties Up With Gene Logic
January 15, 2001
- Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
- SBS Transfers Tagamet to Sumitomo
January 15, 2001
- NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
- SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
- New Health Ministry's Budget Totals \18 Trillion, +4.5% Over FY2000
January 15, 2001
- Fukujin Becomes Hokuho Iyaku's Major Shareholder
January 15, 2001
- Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
- Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
- Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
- BUSINESS NEWS IN BRIEF -1-
January 15, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…